Shionogi obtains FDA approval of ADHD drug Kapvay

10/5/2010 | Drug Store News

Shionogi has gained FDA approval for Kapvay, an extended-release treatment for attention-deficit/hyperactivity disorder patients ages 6 to 17. "We look forward to providing this important, beneficial treatment for ADHD to patients, both as monotherapy and add-on therapy to stimulants," a company official said.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA